Free tool
FAERS Monitor: Zelsuvmi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217424 or its brand name (Zelsuvmi, Berdazimer Sodium). Reports on generic versions are filed under their own applications.
Reports
95
Serious
0
0% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- application site pain46
- application site erythema31
- application site pruritus12
- application site vesicles9
- application site discolouration8
- application site irritation8
- application site rash8
- application site exfoliation6
- wrong technique in product usage process6
- application site inflammation5
- application site eczema4
- application site scab4
- application site swelling4
- application site burn3
- application site dermatitis3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 19 |
| 2026 | 76 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,064 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site eczemaSignal | 4 | 10680.6 | 3996.6 | 31,199 |
| application site inflammationSignal | 5 | 803.0 | 341.6 | 3,232 |
| application site dermatitisSignal | 3 | 713.4 | 233.8 | 1,477 |
| application site painSignal | 46 | 463.3 | 376.3 | 20,739 |
| application site discolourationSignal | 8 | 436.8 | 224.9 | 3,051 |
| application site scabSignal | 4 | 410.8 | 157.3 | 1,249 |
| application site exfoliationSignal | 6 | 323.0 | 148.8 | 1,615 |
| application site vesiclesSignal | 9 | 307.7 | 165.2 | 2,450 |
| application site erythemaSignal | 31 | 262.2 | 196.3 | 7,807 |
| application site swellingSignal | 4 | 177.8 | 68.1 | 537 |
| application site irritationSignal | 8 | 142.4 | 73.4 | 987 |
| application site burnSignal | 3 | 134.9 | 44.3 | 276 |
| application site rashSignal | 8 | 128.9 | 66.4 | 891 |
| application site pruritusSignal | 12 | 117.2 | 69.0 | 1,269 |
| wrong technique in product usage processSignal | 6 | 6.6 | 3.0 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.